MGRX.NASDAQMangoceuticals, INC
10-Q: Mangoceuticals Reports Second Quarter 2024 Results, Highlights Strategic Growth Initiatives
Sentiment:
Quarterly Report
Mangoceuticals, Inc. released its second quarter 2024 financial results, detailing revenue growth, increased operating expenses, and strategic moves including a patent acquisition and new distribution agreement.
Capital raiseThe company sold 1,500 shares of Series B Preferred Stock for $1.65 million and issued warrants to purchase up to 3,300,000 shares of common stock.The company issued 1,000,000 shares of common stock as a commitment fee under an Equity Purchase Agreement.The company has an Equity Purchase Agreement with an institutional investor for up to $25 million in common stock purchases.
Worse than expectedThe company's net loss increased compared to the same period last year.The company's operating expenses increased significantly, outpacing revenue growth.The company's cash balance decreased significantly, indicating a need for additional funding.
Summary
- Mangoceuticals, Inc. reported a net loss of $2.39 million for the three months ended June 30, 2024, and a net loss of $4.76 million for the six months ended June 30, 2024.
- The company's revenue for the three months ended June 30, 2024, was $163,163, and $377,258 for the six months ended June 30, 2024.
- Operating expenses totaled $2.24 million for the three months ended June 30, 2024, and $4.75 million for the six months ended June 30, 2024.
- The company acquired patents related to infection prevention for $20 million, paid through a combination of Series C Preferred Stock and cash.
- Mangoceuticals entered into a distribution agreement with ISFLST, Inc. to expand its product reach in Asia Pacific and Latin America.
- The company completed multiple closings under a Securities Purchase Agreement, raising capital through the sale of Series B Preferred Stock and warrants.
- The company issued 1,000,000 shares of common stock as a commitment fee under an Equity Purchase Agreement.
Sentiment
Score: 4
Explanation: The document presents a mixed picture with positive revenue growth but significant net losses and increasing operating expenses. The company's strategic moves are promising, but the need for additional funding and the risk of dilution are concerning.
Positives
- Revenue increased by 55.9% to $377,258 for the six months ended June 30, 2024, compared to the same period in 2023.
- The company secured a distribution agreement to expand its market reach into Asia Pacific and Latin America.
- The company acquired patents related to infection prevention, potentially opening new product development opportunities.
- The company raised capital through the sale of Series B Preferred Stock and warrants.
Negatives
- The company reported a net loss of $2.39 million for the three months ended June 30, 2024, and a net loss of $4.76 million for the six months ended June 30, 2024.
- Operating expenses increased significantly, driven by higher legal, consulting, and software development costs.
- The company has a working capital deficit of $0.9 million as of June 30, 2024.
- The company's cash balance decreased from $739,006 at the end of 2023 to $490,243 as of June 30, 2024.
Risks
- The company has a history of net losses and may not achieve profitability.
- The company needs additional funding to continue operations and execute its business plan.
- The company's reliance on related party transactions poses a risk.
- The company's products are not approved by the FDA and are produced under an exemption, which may be challenged.
- The company faces competition from existing and new competitors.
- The company's stock price is volatile and subject to dilution from the conversion of preferred stock and exercise of warrants.
- The company's ability to protect its intellectual property is a risk.
Future Outlook
The company plans to continue using the same marketing and management strategies, provide quality products, and seek to expand operations organically or through acquisitions. They also plan to enhance their technology platform and develop new products.
Industry Context
The company operates in the growing men's wellness telemedicine sector, focusing on erectile dysfunction, hair loss, and hormone therapies. The company's strategy includes online sales and partnerships with compounding pharmacies and healthcare professionals.
Comparison to Industry Standards
- The company's revenue growth of 15.5% for the three months ended June 30, 2024, is a positive sign, but the company's net losses are significant and need to be addressed.
- The company's operating expenses are high compared to its revenue, indicating a need for cost management.
- The company's reliance on related party transactions is a risk that needs to be monitored.
- The company's acquisition of patents is a strategic move that could lead to new product development and revenue streams.
- The company's distribution agreement with ISFLST, Inc. is a positive step towards expanding its market reach.
- The company's capital raises through the sale of preferred stock and warrants are necessary to fund operations, but they also cause dilution to existing shareholders.
- Compared to other telemedicine companies, Mangoceuticals is still in an early stage of development and needs to demonstrate sustainable growth and profitability.
Related Party Transactions
- The company has significant related party transactions with Epiq Scripts, LLC, which is 51% owned and controlled by Jacob D. Cohen, the company's Chairman and CEO.
- The company has received loans from Ronin Equity Partners and Cohen Enterprises, Inc., both owned and controlled by Jacob D. Cohen.
- The company sold equipment to Epiq Scripts, a related party, in an arms length transaction.
Stakeholder Impact
- Shareholders face the risk of dilution from the conversion of preferred stock and exercise of warrants.
- Employees may be affected by the company's financial performance and need for additional funding.
- Customers may benefit from the company's expanded product offerings and distribution network.
- Suppliers and creditors may be affected by the company's financial condition and ability to pay its obligations.
Next Steps
- The company plans to continue using the same marketing and management strategies.
- The company plans to continue providing a quality product with excellent customer service.
- The company plans to seek to expand operations organically or through acquisitions as funding and opportunities arise.
- The company plans to make additional and ongoing technology enhancements to its platform.
- The company plans to further develop, market and advertise additional mens health and wellness related products on its telemedicine platform.
- The company plans to identify strategic acquisitions that complement its vision.
Key Dates
| Date | Description |
|---|---|
| 2021-12-09 | Date of a Stock Purchase Agreement with ZipDoctorIncMember |
| 2022-03-17 | Date of a Stock Purchase Agreement |
| 2022-06-15 | Date of a Stock Purchase Agreement with CohenEnterprisesIncMember |
| 2022-08-17 | Date of a Stock Purchase Agreement with CohenEnterprisesIncMember |
| 2022-09-28 | Date of a Lease Agreement |
| 2023-01-03 | Date of a Consulting Agreement with DojoLabsMember |
| 2023-01-06 | Date of Consulting Agreements with BethorLtdMember, RudmanMember, and BoonMember |
| 2023-01-24 | Date of Consulting Agreements |
| 2023-02-28 | Date of Resale Prospectus |
| 2023-03-20 | Date of IPO Underwriting Agreement |
| 2023-03-22 | Date of IPO |
| 2023-04-24 | Date of Private Placement Warrant One |
| 2023-04-25 | Date of Private Placement Warrants Two, Three, and Four |
| 2023-04-26 | Date of Private Placement Warrant Six |
| 2023-05-01 | Date of Private Placement Warrant Seven, HammerMember Employment Agreement, and Private Placement Warrant |
| 2023-05-25 | Date of MrAndrewMember Consulting Agreement |
| 2023-06-01 | Date of MajorDodgeMember Consulting Agreement and StreetGroupLLCMember Production Agreement |
| 2023-06-05 | Date of Private Placement Warrant |
| 2023-06-06 | Date of Private Placement Warrant One |
| 2023-06-07 | Date of Private Placement Warrant Two |
| 2023-06-08 | Date of Private Placement Warrant Three |
| 2023-06-21 | Date of Private Placement Warrant Four |
| 2023-06-22 | Date of Private Placement Warrant Five |
| 2023-06-27 | Date of Private Placement Warrant Six |
| 2023-10-01 | Date of Consulting Agreement with GreentreeFinancialGroupMember |
| 2023-10-10 | Date of Consulting Agreement with LucaConsultingLlcMember |
| 2023-11-01 | Date of Consulting Agreements with JasonSzkupMember and DrDouglasChristiansonMember |
| 2023-11-15 | Date of Consulting Agreement with PHXGlobalLLCMember |
| 2023-12-11 | Date of Marketing Agreement with MariusPharmaceuticalsMember |
| 2023-12-15 | Date of Underwriting Agreement with BousteadSecuritiesLLCMember |
| 2023-12-19 | Date of Follow On Offering |
| 2024-01-02 | Date of Consulting Agreement with GAndPGeneralConsultingMember |
| 2024-01-10 | Date of Consulting Agreement with LucaConsultingLlcMember |
| 2024-01-11 | Date of Consulting Agreement with FirstLevelCapitalMember |
| 2024-01-18 | Date of Underwriters exercising over-allotment option |
| 2024-01-22 | Date of Underwriting Agreement |
| 2024-02-07 | Date of Consulting Agreement with GAndPGeneralConsultingMember |
| 2024-03-01 | Date of loan from RoninEquityPartnersMember |
| 2024-03-18 | Date of loan from CohenEnterprisesIncMember |
| 2024-03-21 | Date of Consulting Agreements with LucaConsultingLlcMember and ZvonimirMoricConsultingMember |
| 2024-03-28 | Date of SeriesBConvertiblePreferredStockMember designation |
| 2024-04-01 | Date of loan from CohenEnterprisesIncMember |
| 2024-04-04 | Date of Securities Purchase Agreement |
| 2024-04-05 | Date of Securities Purchase Agreement and Equity Purchase Agreement |
| 2024-04-08 | Date of Equity Purchase Agreement |
| 2024-04-18 | Date of SixPercentageSeriesCConvertibleCumulativePreferredStockMember designation |
| 2024-04-24 | Date of IPPurchaseAgreementMember |
| 2024-04-25 | Date of Consulting Agreement with PHXGlobalLLCMember |
| 2024-04-26 | Date of Second Closing under Securities Purchase Agreement |
| 2024-04-28 | Date of SharePurchaseAgreementMember |
| 2024-05-15 | Date of StockPurchaseAgreementMember |
| 2024-05-17 | Date of Second Closing under Securities Purchase Agreement |
| 2024-05-21 | Date of EquityPurchaseAgreementMember |
| 2024-05-22 | Date of EquityPurchaseAgreementMember |
| 2024-05-23 | Date of Consulting Agreement with AcornManagementPartnersLLCMember |
| 2024-05-24 | Date of EquityPurchaseAgreementMember |
| 2024-06-05 | Date of OfficersDirectorsAndEmployeesMember stock grants |
| 2024-06-28 | Date of ThridClosingDateMember |
| 2024-07-08 | Date of Series B Preferred Stock conversion |
| 2024-07-09 | Date of Master Distribution Agreement with ISFLST, Inc. |
| 2024-07-25 | Date of Series B Preferred Stock conversion |
| 2024-07-30 | Date of Consulting Agreement with JohnDorseyMember |
Keywords
telemedicine, erectile dysfunction, hair loss, mens wellness, pharmaceuticals, preferred stock, warrants, patent acquisition, distribution agreement, capital raise
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.